Search Results - "Fox, Stephanie Y."

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study by Moskowitz, Alison J, Dr, Schöder, Heiko, Prof, Yahalom, Joachim, Prof, McCall, Susan J, NP, Fox, Stephanie Y, BS, Gerecitano, John, MD, Grewal, Ravinder, MD, Hamlin, Paul A, MD, Horwitz, Steven, MD, Kobos, Rachel, MD, Kumar, Anita, MD, Matasar, Matthew, MD, Noy, Ariela, MD, Palomba, M Lia, MD, Perales, Miguel-Angel, MD, Portlock, Carol S, Prof, Sauter, Craig, MD, Shukla, Neerav, MD, Steinherz, Peter, Prof, Straus, David, Prof, Trippett, Tanya, MD, Younes, Anas, Prof, Zelenetz, Andrew, Prof, Moskowitz, Craig H, Prof

“…Summary Background Pre-transplantation18 F-fluorodeoxyglucose (FDG) PET-negativity is one of the strongest predictors of outcome after high-dose therapy and…”
Get full text

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma by Moskowitz, Alison J., Schöder, Heiko, Gavane, Somali, Thoren, Katie L., Fleisher, Martin, Yahalom, Joachim, McCall, Susan J., Cadzin, Briana R., Fox, Stephanie Y., Gerecitano, John, Grewal, Ravinder, Hamlin, Paul A., Horwitz, Steven M., Kumar, Anita, Matasar, Matthew, Ni, Andy, Noy, Ariela, Palomba, M. Lia, Perales, Miguel-Angel, Portlock, Carol S., Sauter, Craig, Straus, David, Younes, Anas, Zelenetz, Andrew D., Moskowitz, Craig H.

“…Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted…”
Get full text